HIV drug resistance, viral suppression, and survival in children living with HIV in Brazil

• Published in: HIV medicine 2024-09
• Main Authors: Mendes-Ferreira, Alexandre A C, Véras, Nazle Mendonça Collaço, Pinho, Rosana Elisa Gonçalves Gonçalves, Pascom, Ana Roberta, Gama, Lúcio, Avelino-Silva, Vivian I
• Format: Article
• Language: English
• ISSN: 1464-2662; 1468-1293; 1468-1293
• DOI: 10.1111/hiv.13714

Mutations associated with HIV drug resistance (DR) affect clinical outcomes. Understanding the prevalence of HIV DR and its association with viral suppression and survival in the paediatric population is key to inform patient care and health policies. We used Brazilian monitoring systems to identify genotyping tests performed in children living with HIV aged ≤18 months between 2009 and 2020. We categorized HIV DR using three criteria: any HIV DR (R ), DR to nevirapine or efavirenz (R ), and DR to at least one antiretroviral recommended for children with HIV in Brazilian guidelines (R ). We investigated factors associated with HIV DR, viral suppression, and survival up to 3 years old using multivariable models. Lastly, we describe the annual prevalence of each type of HIV DR in Brazilian children with HIV between 2009 and 2020. We included 1152 children with HIV with a median age of 5 months at genotype testing; 57% were females. R was observed in 30%, R in 17%, and R in 21%. Children with HIV whose birth parents were exposed to nevirapine or efavirenz before delivery had higher odds of R (odds ratio 3.4; 95% confidence interval [CI] 1.1-10.8). Children with HIV with R or R had higher rates of death than those with HIV with no HIV DR in the adjusted models (adjusted hazard ratios 4.7 [95% CI 1.6-13.9] and 4.1 [95% CI 1.4-12.4], respectively). The prevalence of resistance to nevirapine and efavirenz peaked in 2015. Over time, the prevalence of genotyping tests with no detected resistance varied between 57% and 87%. HIV DR is highly prevalent in children with HIV and is associated with lower survival.